Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
D000505:Alopecia / Q000139:chemically induced; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis; D013280:Stomatitis / Q000139:chemically induced; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
D005047:Etoposide; D011034:Podophyllotoxin